JAMA February 5 Tenecteplase for Acute Non–Large Vessel Occlusion 4.5 to 24 Hours After Ischemic Stroke

The OPTION trial investigated whether the clot-dissolving drug tenecteplase could improve recovery for stroke patients who arrived at the hospital between 4.5 and 24 hours after their symptoms began. By focusing on individuals with non-large vessel occlusions and imaging evidence of salvageable brain tissue, researchers found that those receiving the medication were significantly more likely to achieve an excellent functional outcome compared to those receiving standard care. However, while the treatment improved long-term independence, it also carried a statistically higher risk of symptomatic intracranial hemorrhage. Ultimately, this study suggests that the therapeutic windowfor specialized stroke intervention may be safely extended for a specific subset of patients, provided the benefits are weighed against potential bleeding risks.